Status:
COMPLETED
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Lead Sponsor:
Helsinn Therapeutics (U.S.), Inc
Conditions:
Mycosis Fungoides
Eligibility:
All Genders
18+ years
Brief Summary
The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) who are rece...
Detailed Description
This is a multi-center, prospective, observational, US-based drug study. All consecutive Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) patients being treated with Valchlor will be invited to e...
Eligibility Criteria
Inclusion
- All adult patients (≥ 18 years of age) diagnosed with MF CTCL and being treated with Valchlor. This includes patients newly initiating Valchlor OR patients continuing treatment with Valchlor:
- Patients newly initiating Valchlor are patients who have their first office visit after having initiated Valchlor.
- Patients continuing treatment with Valchlor includes patients who are actively taking Valchlor on the day of enrollment.
- Signed patient informed consent.
Exclusion
- • None
Key Trial Info
Start Date :
November 12 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 17 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT02296164
Start Date
November 12 2014
End Date
October 17 2018
Last Update
March 4 2020
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigator Site
Little Rock, Arkansas, United States, 72205
2
Investigator Site
Duarte, California, United States, 91010
3
Investigator Site
La Mesa, California, United States, 91941
4
Investigator Site
San Francisco, California, United States, 94115